Today: 9 April 2026
Seagate stock jumps 21% after forecast beat as AI storage demand tightens
28 January 2026
1 min read

Seagate stock jumps 21% after forecast beat as AI storage demand tightens

New York, January 28, 2026, 11:52 EST — Regular session

  • Seagate Technology Holdings (STX) jumped roughly 21% in late morning trading, climbing to a new peak close to $449
  • The hard-drive manufacturer beat quarterly estimates and issued guidance that surpassed Wall Street expectations
  • Storage peers climbed, reacting ahead of the Fed’s decision due Wednesday

Seagate Technology Holdings plc shares surged roughly 21%, hitting $448.79 in late morning trading Wednesday. The data-storage giant outperformed quarterly forecasts and projected revenue and profit for the current quarter that topped Wall Street’s predictions.

The rally is significant since Seagate’s nearline hard disk drives are a key component in large data centers. Investors often view the company’s order flow as a rough barometer for how much the AI expansion is straining hardware budgets.

Seagate’s jump helped power a chip-fueled rally that pushed U.S. stocks into uncharted territory, with the S&P 500 clearing the 7,000 threshold. “These big round numbers can be difficult psychological tests for the market,” said Jeff Buchbinder, chief equity strategist at LPL Financial, noting that risk appetite stayed firm ahead of major events unfolding later in the day. Reuters

Seagate is aiming for third-quarter revenue around $2.90 billion, give or take $100 million, beating the $2.77 billion average estimate analysts had, per LSEG data. The company also forecast adjusted earnings per share at $3.40, plus or minus 20 cents, topping the $2.96 expected. This follows second-quarter results showing revenue of $2.83 billion and adjusted earnings of $3.11 a share. Reuters

In its earnings release, CEO Dave Mosley highlighted the quarter’s record profitability and pointed to the “ongoing ramp” of HAMR-based Mozaic products. HAMR—heat-assisted magnetic recording—is Seagate’s tech for cramming more data onto each drive, a crucial edge as cloud clients demand higher capacity. investors.seagate.com

Storage stocks tracked the move. Western Digital climbed roughly 10%, while Sandisk added about 8%. Both are set to release earnings after Thursday’s close. Western Digital

UBS bumped up its price target to $385 but stuck with a Neutral rating. Analyst Timothy Arcuri flagged a “stretched valuation” despite applauding Seagate’s “strong execution” and better margins. Investing.com

Interest rates remain the central focus. The Federal Reserve is widely expected to keep rates unchanged, with investors keenly analyzing both the statement and Chair Jerome Powell’s remarks for clues on future moves. Seema Shah of Principal Asset Management noted there’s “no urgency to lower rates aggressively.” Reuters

Seagate bulls now await Thursday’s storage earnings to see if tight supply and firm pricing will carry through into 2026. The real question: can today’s jump stick after the post-earnings volatility fades?

Stock Market Today

  • AbbVie's Humira Launch on TrumpRx with 86% Discount Sparks Valuation Questions
    April 9, 2026, 9:02 AM EDT. AbbVie (NYSE:ABBV) has introduced Humira on the TrumpRx platform at an 86% discount under a White House pricing deal aiming to reduce patient costs and widen drug access. This marks a significant US pricing strategy shift post exclusivity for Humira, a key immunology therapy driving substantial revenue. The stock trades near $206.69, about 20% below analyst targets and 43.8% under fair value estimates. The deep discount could alter patient volume, payer ties, and pricing benchmarks in government-linked drug programs. AbbVie's revenue exposure of $61.2 billion and a high price-to-earnings ratio of 87.3 place focus on potential impacts to cash flow and dividends amid its debt load. Investors should monitor reactions from payers, competitors, and capital markets to this pricing shift that could redefine AbbVie's US market dynamics.

Latest article

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
Lam Research stock price wobbles ahead of earnings as Wall Street braces for a big move
Previous Story

Lam Research stock price wobbles ahead of earnings as Wall Street braces for a big move

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal
Next Story

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Go toTop